NeutraKine® IFN beta Monoclonal antibody
NeutraKine® IFN beta Monoclonal Antibody for Neutralization,ELISA
Host / Isotype
Mouse / IgG1
Cat no : 69013-1-Ig
69013-1-Ig targets NeutraKine® IFN beta in Neutralization,ELISA applications and shows reactivity with Human samples.
|Host / Isotype||Mouse / IgG1|
|Immunogen||human NeutraKine® IFN beta protein HZ-1298|
|Full Name||IFN beta|
|Gene ID (NCBI)||3456|
|Purification Method||Protein G purification|
|Storage Buffer||Sterile PBS.|
|Reconstitution||This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.|
|Stability and Storage||Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.|
Interferon beta (IFN beta) is a cytokine that is naturally produced by the immune system in response to biological and chemical stimuli. It signals by binding to the heterodimeric type I IFN receptor composed of the IFNAR1 and IFNAR2 chains, and regulates the expression of a plethora of genes by means of the classical JAK/STAT and other pathways. Interferon beta (IFN beta) has been shown in several clinical trials to have efficacy in multiple sclerosis. Interferon beta gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies.
This antibody is used to Block/Neutralize IFN beta protein.